Citations 2
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
Volpi, Simona , Bult, Carol J. , Chisholm, Rex L. , Deverka, Patricia A. , Jacob, Howard J., Kasapi, Melpomeni , McLeod, Howard L. , Roden, Dan M. , Green, Eric D. , Rodriguez, Laura Lyman , Aronson, Samuel , Cavallari, Larisa H. , Denny, Joshua C. , Dressler, Lynn G., Johnson, Julie A. , Leeder, J. Steven , Piquette‐Miller, Micheline , Rasmussen‐Torvik, Laura J. , Ritchie, Marylyn D. , Skaar, Todd C. , Wagle, Nikhil , Weinshilboum, Richard M. , Weitzel, Kristin, Wildin, Robert S. , Manolio, Teri A. , Relling, Mary V. , Weinshilboum, Richard, Denny, Joshua C , Ginsburg, Geoffrey S. , Roden, Dan M. , Williams, Marc S , Klein, Teri E. , Perera, Minoli A. , Rehm, Heidi L. , Weinshilboum, Richard M. , Wilson, John T. , Cavallari, Larisa H , Rasmussen-Torvik, Laura J
Clinical Pharmacology & Therapeutics | February 21, 2018 | Volume: 103 | Issue: 5 | Pages: 778-786
Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J K, Bishop, JR, Dj, Müller, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, Adrián , Skaar, TC, Scott, Stuart A. , Stingl, Julia , Klein, Teri E. , Caudle, KE, Leeder, J. Steven , Müller, Daniel J. , Sangkuhl, Katrin , Ji, Yuan , Skaar, T.C., Gaedigk, Andrea , LLerena, Adrián , Müller, Daniel J , Klein, Teri E , Scott, Stuart A
Clinical Pharmacology & Therapeutics | May 13, 2015 | Volume: 98 | Issue: 2 | Pages: 127-134
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org ).